It is well known that inflammatory conditions in selected organs increase the risk of cancer. Compounds of the inflammatory tumor microenvironment include leukocytes, cytokines, complement components, are orchestrated by transcription factors, such as STAT-3 (Signal Transducer and Activator of Transcription 3) and NF-kB. Therefore drugs able to inhibit one or both transcription factors could be useful tools to treat cancer disease. Two main approaches have been explored to inhibit STAT-3 signalling: • indirect, inhibiting the upstream tyrosine kinases that are responsible for STAT-3 activation or blocking factors such as JAK, Src, Bcr-Abl, FLT3 and EGFR that are involved in the activation of STAT-3 signalling. This kind of inhibition induces tumour-cell apoptosis but is poor selective. • direct, by interaction of small molecules with the protein. In this selective approach the starting point is the crystallographic structure of STAT-3 SH2 domain. S-methyl methanethiosulfonate, isolated from cauliflower has been shown to inhibit colon tumor incidence when administered to rats during the post-initiation phase of carcinogenesis . Recently, a new methanethiosulfonate derivative of valproic acid (ACS33) was reported by some of us to show good in vitro antiproliferative activity and to inhibit in vivo the growth of PC3 in subcutaneous xenograft mice models . Fig.1: Structures of the studied thiosulfonate hybrids. Since the influence of methanethiosulfonates on STAT-3 activity has not been yet studied, we decided to synthesize a set of thiosulfonate-drug hybrids (Fig.1) and to submit them and their parent compounds to the AlphaScreen-based assay, to investigate their ability to bind STAT-3 SH2 domain. Moreover, in order to check the selectivity of our molecules on STAT-3, other SH2-containing proteins, such as STAT-1, exhibiting a high degree of sequence homology to STAT-3, have also been tested. Results showed that most of the synthesized thiosulfonate-hybrids are able to strongly and selectively bind STAT-3 SH2 domain, whereas the parent drugs were completely devoid of this ability. Studies are ongoing to better define the profile of our new methanethiosulfonate derivatives as potential dual STAT-3/NFkB inhibitors. References 1. Reddy, B. S.; Kawamori, T.; Lubet, R.; Steele, V.; Kelloff, G.; Rao, C. V. Chemopreventive effect of S-methylmethane thiosulfonate and sulindac administered together during the promotion/progression stages of colon carcinogenesis Carcinogenesis 1999, 20, 1645-8. 2. Wedel S. A.; Sparatore A.; Del Soldato P.; Al-Batran S. E.; Atmaca A.; Juengel E.; Hudak L.; Jonas D.; Blaheta R. A. New histone deacetylase inhibitors as potential therapeutics tools for advanced prostate carcinoma. J. Cell. Mol Med 2008, 12, 2457-66.
|Titolo:||Methanethiosulfonate derivatives as ligands of STAT3-SH2 domain|
|Data di pubblicazione:||giu-2014|
|Settore Scientifico Disciplinare:||Settore CHIM/08 - Chimica Farmaceutica|
|Citazione:||Methanethiosulfonate derivatives as ligands of STAT3-SH2 domain / E. Gabriele, A. Barteselli, V. Moiana, F. Porta, A. Gelain, A. Asai, A. Sparatore. ((Intervento presentato al 8. convegno Meeting Nuove Prospettive in Chimica Farmaceutica tenutosi a Parma nel 2014.|
|Appare nelle tipologie:||14 - Intervento a convegno non pubblicato|